AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03969004 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) infusion over 30 minutes
Study NCT03467750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Patients in this group will receive 0.5mg/kg of ketorolac, administered intravenously.
Study NCT03467750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.
Study NCT03467750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: All patients will undergo inhalational induction with nitrous oxide and sevoflurane. After intravenous (IV) placement, 1-3mg/kg of propofol and 1mcg/kg of fentanyl will be administered. After induction, 0.5mg/kg of dexamethasone and an IV infusion of 15mg/kg of acetaminophen will be administered. During surgery, 0.5mcg/kg of dexmedetomidine and 0.1mg/kg ondansetron will be given.~A rescue dose of 0.5-1mcg/kg of IV Fentanyl will be available for use at the end of the procedure. The decision to administer will be left to the discretion of the attending anesthesiologist. The choice to give this will be made based on variables including patient's condition and a 20% increase in the heart rate and blood pressure.~The PACU nurses, who will be blinded to ketorolac administration, will evaluate the patients using FLACC scores. For patients with a FLACC score of 6-10, morphine 0.05mg/kg will be administered. For patients with FLACC scores of 3-5, morphine 0.025mg/kg will be administered.
Study NCT04574271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary advice and exercise prescription
Description: Personalized dietary advice and exercise prescription according to nutritional status.
Study NCT04574271 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual dietary advice and exercise prescription
Description: Generalized dietary advice and excercise prescription in elder patients.
Study NCT04253691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Mediated Relaxation
Description: Participants will use a brief Virtual Reality relaxation protocol to improve their insomnia. Their workbook will contain a handout that outlines the details. Participants will be encouraged to refer to it at home if they forget any part of the procedure.
Study NCT03143166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazol sodium
Description: Tablet
Study NCT00241852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma: It's a Family Affair!
Description: Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
Study NCT00241852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma and Stress Comparator
Description: Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
Study NCT00861523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiamine & promethazine
Description: thiamine 100 mg IV promethazine 25 mg IV
Study NCT03107234 — intervention group
Intervention type: OTHER
Intervention: Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
Description: Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
Study NCT04262752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent colonic exo-peristaltic massage treatment with the MOWOOT medical device
Description: The MOWOOT massager belt is connected to the desktop device and is the component which is in contact with the subject giving the abdominal massage action.~The massager belt, which is placed on the user's abdominal area, administers a specific abdominal massage on the ascendant and descendent segments of the colon. This massage emulates the techniques used by professional therapists through a series of pneumatic actuators operating like the movement of a wave transmitting movement through the colon. The type and speed of the massage can usually be regulated by an algorithm that controls the operation from the desktop device.~For the present clinical trial, time and force will stay fixed on 20 minutes and force 3 (0'6-0'7 bar). Subjects will not be able to choose other massage options. Subjects should use the MOWOOT device once a day for 20 min (1 complete treatment) ideally at the same hour every day for the 4 weeks of the interventional treatment period.
Study NCT03324451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TTM Intervention for Insulin Initiation
Description: The intervention contains two parts: (1) individual intervention; (2) insulin injection follow-up management. Different intervention strategies are applied to patients according to their stages of change.
Study NCT03324451 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Regular patient education on insulin injection at the control arm hospital.
Study NCT00502086 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid (nutritional supplement)
Description: Viusid three sachets daily during 96 weeks
Study NCT00502086 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three sachets daily during 96 weeks
Study NCT00588653 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through
Description: Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
Study NCT01030406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40/0mg taken first
Description: 8x Oxycodone/Niacin 5/0mg tablets All arms taken with a 48 hour washout between doses
Study NCT01030406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 80/0mg taken first
Description: 8x Oxycodone/Niacin 10/0mg tablets All arms taken with a 48 hour washout between doses
Study NCT01030406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40/240mg taken first
Description: 8x Oxycodone/Niacin 5/30mg tablets All arms taken with a 48 hour washout between doses
Study NCT01030406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80/480mg taken first
Description: 8x Oxycodone/Niacin 10/60mg tablets All arms taken with a 48 hour washout between doses
Study NCT01030406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0/0mg taken first
Description: Placebo All arms taken with a 48 hour washout between doses
Study NCT03952325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Tesetaxel at 27 mg/m2 orally Q3W
Study NCT03952325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab at 360 mg by intravenous infusion Q3W
Study NCT03952325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab at 200 mg by intravenous infusion Q3W
Study NCT03952325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab at 1,200 mg by intravenous infusion Q3W
Study NCT03493464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR55
Description: A novel targeted ultrasound contrast agent
Study NCT06593743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perianal NRL001 Gel 3 strengths
Description: A single application of 0.3%, 1.0%, 3.0% NRL001 gel in stepwise dose ascending fashion.
Study NCT06593743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraanal NRL001 Gel 2 strengths
Description: A single application of 3.0% or 1.0% Gel
Study NCT06593743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrarectal NRL001 Gel
Description: A single application of 1.0% Gel
Study NCT06593743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRL001: 10mg suppository
Description: NRL001 10mg suppository applied to rectum.
Study NCT04538690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoulder Exercises
Description: Exercises consist of shoulder range of motion, releasing exercises, strength training, stretching.
Study NCT04538690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy
Description: TENS, US
Study NCT01990118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: Neoral® capsule containing 25mg or 100mg cyclosporine
Study NCT01990118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gengraf® capsule containing 25mg or 100mg cyclosporine
Description: Transplant patients who were stable on Neoral were converted to Gengraf
Study NCT05148143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed combined with oxaplatin
Description: Raltitrexed combined with oxaplatin as second line treatment of cholangiocarcinoma
Study NCT00476710 — intervention group
Intervention type: DRUG
Intervention: Colesevelam HCl
Study NCT00682669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR
Description: A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
Study NCT00682669 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HLC
Description: An 8-week program consisting of lectures and discussion of health-related topics.
Study NCT06595771 — intervention group
Intervention type: DEVICE
Intervention: continuous positive airway pressure
Description: continuous positive airway pressure is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in people who are able to breathe spontaneously on their own, but need help keeping their airway unobstructed
Study NCT06595771 — intervention group
Intervention type: DEVICE
Intervention: Polysomnography
Description: Polysomnography measures Apnea-hypopnea index (Minutes)~Classify and identify Obstructive Sleep Apnea Syndrome (OSAS):~1. Apnea-hypopnea index: 5-14.9 olan; mild OSAS~2. Apnea-hypopnea index: 15-29.9: moderate OSAS~3. Apnea-hypopnea index ≥30: severe OSAS measures duration and percentage of time oxygen saturation dropped below 90% the total minutes of sleep
Study NCT06591156 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Root coverage
Description: Treatment of gingival recession, Miller\&#39;s Class I or Cairo\&#39;s RT1, which is the most predictable group to receive interventions without any impairment or problem for the patients.~After local anesthesia, a horizontal incision was made, delimitating the coronal part of the flap. This horizontal incision of the envelope flap consists of an oblique submarginal incision in the interdental areas that creates a surgical papilla. The incisions continue with the intrasulcular incision in the recession defects and are extended to form an envelope flap between the central and molar. This design facilitates the planned coronal repositioning of the flap tissue on the exposed root surfaces.~The apical gingival tissue at root exposures is raised to a full thickness to provide the critical part of the flap for root coverage with more thickness. Finally, the most apical portion of the flap is elevated in a split-thickness to facilitate coronal displacement of the flap.
Study NCT06591156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Coronally advanced flap without any graft or biomaterial
Study NCT06586554 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: The SS group received static stretching, which was applied with gentle and firm pressure while pulling opposite the hamstring muscle contraction.
Study NCT06586554 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial release
Description: Myofascial release is applied with cross-handed stretches over hamstring muscle
Study NCT04370210 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Child of both groups enrolled, and their parents, must complete online questionnaires
Study NCT03760718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free 1% Chloroprocaine
Description: 40 ml of preservative-free 1% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
Study NCT03760718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free 2% Chloroprocaine
Description: 40 ml of preservative-free 2% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
Study NCT03760718 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preservative free 3% Chloroprocaine
Description: 40 ml of preservative-free 3% chloroprocaine is planned for administration into the peritoneal cavity after delivery of the baby.
Study NCT00811590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.~Everolimus is being investigated as an anticancer agent based on its potential to act~* directly on the tumor cells by inhibiting tumor cell growth and proliferation~* indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells.
Study NCT03444350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gaseous ozone
Description: SRP plus gaseous ozone
Study NCT03444350 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SRP plus placebo
Description: only SRP
Study NCT01078454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given PO
Study NCT01078454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given PO
Study NCT01078454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01406964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAT test
Description: A CAT test is performed in order to diagnose tubal factor causes
Study NCT01406964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histerosalpingography
Description: A Histerosalpingography is performed.
Study NCT01685671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60μg
Description: Administrated NESP 60μg once subcutaneously
Study NCT01685671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-11101 60μg
Description: Administrated CKD-11101 60μg once subcutaneously
Study NCT02988622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fraxel Laser
Description: One half of the scar is treated with Fraxel Laser
Study NCT02988622 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO2 Laser
Description: One half of the scar is treated with CO2 Laser.
Study NCT02447172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Collagen sponge
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Study NCT02447172 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo sponge
Study NCT03261700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE
Description: This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV and red flags, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
Study NCT03261700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information and referral condition
Description: Participants randomized to this arm will receive a brochure-based intervention, consisting of education, support and problem solving, safety planning as well as resources and referrals to address an array of health and social issues associated with IPV (including in VA and the community).
Study NCT02617303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OTAGO's exercises
Description: The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 6 weeks (2 sessions per week) and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
Study NCT02617303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: COMMON PRACTICE
Description: Normal medical treatment will be provided by family physicians and nurses.
Study NCT04331496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic solution
Description: Hypertonic serum 4 ml 3%, administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
Study NCT04331496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological solution
Description: Single-dose physiological saline serum (5 ml 0.9% NaCl), administered for 8 minutes in a Philips® vibrating mesh nebulizer plus 20 minute session of Respiratory Physiotherapy based on slow expiratory flow: passive technique of expiratory aid applied to the participant by means of a slow thoracic-abdominal pressure that begins at the end of a spontaneous expiration and continues until the residual volume. The physiotherapist through assisted cough or stimulation of the trachea achieves expectoration of sputum.
Study NCT03411447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Study NCT03411447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enteral nutrition
Study NCT00600886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
Study NCT00600886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: Octreotide LAR - i.m. depot injection given once every 28 days.
Study NCT01629602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the Boomerang Nerve Flap
Description: The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
Study NCT04185454 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Jarlsberg cheese
Description: Daily intake of Jarlsberg cheese
Study NCT03073954 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Working memory training
Description: The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.~The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected.